Evidence map›Paper›PMID 31794625›Full record

Trial reportJAMA2019

Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.

Peter J Hoskin, Kirsten Hopkins, Vivek Misra, Tanya Holt, Rhona McMenemin, Danny Dubois, Fiona McKinna, Bernadette Foran, Krishnaswamy Madhavan, Carol MacGregor and 14 more

Abstract readComparative StudyEquivalence TrialMulticenter Study
In one paragraph

Trial report in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Evaluating ambulatory function as an outcome following treatment for spinal metastases: a systematic review.The spine journal : official journal of the North American Spine Society · 2021
    Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Evidence-based management of metastatic spinal cord compression (MSCC): expert recommendations for standardizing care in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Peter J HoskinMount Vernon Cancer Centre, Northwood, United Kingdom.
Kirsten HopkinsBristol Centre for Haematology and Oncology Bristol, Bristol, United Kingdom.
Vivek MisraThe Christie Hospital, Manchester, United Kingdom.
Tanya HoltPrincess Alexandra Hospital, University of Queensland, Brisbane, Australia.
Rhona McMeneminThe Freeman Hospital, Newcastle, United Kingdom.
Danny DuboisQueen Alexandra Hospital, Portsmouth, United Kingdom.
Fiona McKinnaRoyal Sussex County Hospital, Brighton, United Kingdom.
Bernadette ForanWeston Park Hospital, Sheffield, United Kingdom.
Krishnaswamy MadhavanSouthend University Hospital, United Kingdom.
Carol MacGregorRaigmore Hospital, Inverness, United Kingdom.
Andrew BatesSouthampton General Hospital, Southampton, United Kingdom.
Noelle O'RourkeThe Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Jason F LesterVelindre Cancer Centre, Cardiff, United Kingdom.
Tim SevittKent Oncology Centre, Maidstone, United Kingdom.
Daniel RoosRoyal Adelaide Hospital, Adelaide, Australia.
Sanjay DixitCastle Hill Hospital, Hull, United Kingdom.
Gillian BrownWeston Park Hospital, Sheffield, United Kingdom.
Seonaid ArnottRaigmore Hospital, Inverness, United Kingdom.
Sharon Shibu ThomasSouthend University Hospital, United Kingdom.
Sharon ForsythCRUK & UCL Cancer Trials Centre, London, United Kingdom.
Sandy BeareCRUK & UCL Cancer Trials Centre, London, United Kingdom.
Krystyna ReczkoCRUK & UCL Cancer Trials Centre, London, United Kingdom.
Allan HackshawCRUK & UCL Cancer Trials Centre, London, United Kingdom.
Andre LopesCRUK & UCL Cancer Trials Centre, London, United Kingdom.

Funding

Cancer Research UK 11408
6 · The paper itself

Abstract

Importance: Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there is no standard radiotherapy regimen. Objective: To evaluate whether single-fraction radiotherapy is noninferior to 5 fractions of radiotherapy. Design, Setting, and Participants: Multicenter noninferiority randomized clinical trial conducted in 42 UK and 5 Australian radiotherapy centers. Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area. Patients were recruited between February 2008 and April 2016, with final follow-up in September 2017. Interventions: Patients were randomized to receive external beam single-fraction 8-Gy radiotherapy (n = 345) or 20 Gy of radiotherapy in 5 fractions over 5 consecutive days (n = 341). Main Outcomes and Measures: The primary end point was ambulatory status at week 8, based on a 4-point scale and classified as grade 1 (ambulatory without the use of aids and grade 5 of 5 muscle power) or grade 2 (ambulatory using aids or grade 4 of 5 muscle power). The noninferiority margin for the difference in ambulatory status was -11%. Secondary end points included ambulatory status at weeks 1, 4, and 12 and overall survival. Results: Among 686 randomized patients (median [interquartile range] age, 70 [64-77] years; 503 (73%) men; 44% had prostate cancer, 19% had lung cancer, and 12% had breast cancer), 342 (49.8%) were analyzed for the primary end point (255 patients died before the 8-week assessment). Ambulatory status grade 1 or 2 at week 8 was achieved by 115 of 166 (69.3%) patients in the single-fraction group vs 128 of 176 (72.7%) in the multifraction group (difference, -3.5% [1-sided 95% CI, -11.5% to ∞]; P value for noninferiority = .06). The difference in ambulatory status grade 1 or 2 in the single-fraction vs multifraction group was -0.4% (63.9% vs 64.3%; [1-sided 95% CI, -6.9 to ∞]; P value for noninferiority = .004) at week 1, -0.7% (66.8% vs 67.6%; [1-sided 95% CI, -8.1 to ∞]; P value for noninferiority = .01) at week 4, and 4.1% (71.8% vs 67.7%; [1-sided 95% CI, -4.6 to ∞]; P value for noninferiority = .002) at week 12. Overall survival rates at 12 weeks were 50% in the single-fraction group vs 55% in the multifraction group (stratified hazard ratio, 1.02 [95% CI, 0.74-1.41]). Of the 11 other secondary end points that were analyzed, the between-group differences were not statistically significant or did not meet noninferiority criterion. Conclusions and Relevance: Among patients with malignant metastatic solid tumors and spinal canal compression, a single radiotherapy dose, compared with a multifraction dose delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome (ambulatory at 8 weeks). However, the extent to which the lower bound of the CI overlapped with the noninferiority margin should be considered when interpreting the clinical importance of this finding. Trial Registration: ISRCTN Identifiers: ISRCTN97555949 and ISRCTN97108008.

Indexed as

Dose Fractionation, RadiationNeoplasm MetastasisAdultAgedAged, 80 and overFemaleHumansKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsRadiation DosageRadiotherapySpinal Cord CompressionSurvival Rate

Identifiers

PMID31794625
PMCPMC6902166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.